Verici Dx (Verici Dx) Other Stockholders Equity : $3.27 Mil (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Other Stockholders Equity?

Verici Dx's Other Stockholders Equity for the quarter that ended in Jun. 2023 was $3.27 Mil.

Verici Dx's quarterly Other Stockholders Equity declined from Jun. 2022 ($2.98 Mil) to Dec. 2022 ($2.82 Mil) but then increased from Dec. 2022 ($2.82 Mil) to Jun. 2023 ($3.27 Mil).

Verici Dx's annual Other Stockholders Equity increased from Dec. 2020 ($3.82 Mil) to Dec. 2021 ($4.51 Mil) but then declined from Dec. 2021 ($4.51 Mil) to Dec. 2022 ($2.82 Mil).

Verici Dx Other Stockholders Equity Historical Data

The historical data trend for Verici Dx's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Other Stockholders Equity Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Other Stockholders Equity

3.82

4.51

2.82

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23
Other Stockholders Equity	4.23	4.51	2.98	2.82	3.27

Verici Dx Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Verici Dx Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Verici Dx's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx (Verici Dx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines